{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T12:42:40Z","timestamp":1791290560182,"version":"4.3.0"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T00:00:00Z","timestamp":1732233600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","award":["IND228"],"award-info":[{"award-number":["IND228"]}],"id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000521","name":"Canadian Cancer Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000521","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000015","name":"Canadian Cancer Society Research Institute","doi-asserted-by":"publisher","award":["707213"],"award-info":[{"award-number":["707213"]}],"id":[{"id":"10.13039\/501100000015","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.eclinm.2024.102991","type":"journal-article","created":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T06:34:14Z","timestamp":1733812454000},"page":"102991","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Durvalumab and tremelimumab in patients with advanced rare cancer: a multi-centre, non-blinded, open-label phase II basket trial"],"prefix":"10.1016","volume":"79","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0825-5070","authenticated-orcid":false,"given":"Abha A.","family":"Gupta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Tinker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek","family":"Jonker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahma","family":"Jamal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hal","family":"Hirte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8829-5979","authenticated-orcid":false,"given":"Eric W.","family":"Winquist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4814-3126","authenticated-orcid":false,"given":"Quincy","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Kollmannsberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Alcindor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torsten O.","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9160-5405","authenticated-orcid":false,"given":"Ming","family":"Tsao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tricia R.","family":"Cottrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Provencher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Hilton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika K.","family":"Krzy\u017canowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Elser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastien","family":"Hotte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joana","family":"Sederias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siwei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet","family":"Dancey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eclinm.2024.102991_bib1","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/j.1600-065X.2008.00662.x","article-title":"Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways","volume":"224","author":"Fife","year":"2008","journal-title":"Immunol Rev"},{"issue":"10","key":"10.1016\/j.eclinm.2024.102991_bib2","first-page":"674","article-title":"PD-1-targeted immunotherapy: recent clinical findings","volume":"10","author":"Brahmer","year":"2012","journal-title":"Clin Adv Hematol Oncol"},{"issue":"19","key":"10.1016\/j.eclinm.2024.102991_bib3","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma","volume":"378","author":"Eggermont","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.eclinm.2024.102991_bib4","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"issue":"19","key":"10.1016\/j.eclinm.2024.102991_bib5","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma","volume":"377","author":"Weber","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.eclinm.2024.102991_bib6","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2217\/imt.13.9","article-title":"Tremelimumab: a review of development to date in solid tumors","volume":"5","author":"Tarhini","year":"2013","journal-title":"Immunotherapy"},{"key":"10.1016\/j.eclinm.2024.102991_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/nyas.12180","article-title":"Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma","volume":"1291","author":"Wolchok","year":"2013","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.eclinm.2024.102991_bib8","doi-asserted-by":"crossref","first-page":"e450","DOI":"10.1200\/EDBK_158712","article-title":"Immunotherapy: beyond anti-PD-1 and anti-PD-L1 therapies","volume":"35","author":"Antonia","year":"2016","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"21","key":"10.1016\/j.eclinm.2024.102991_bib9","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","article-title":"Nivolumab plus ipilimumab in advanced non-small-cell lung cancer","volume":"381","author":"Hellmann","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.eclinm.2024.102991_bib10","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1158\/1940-6207.CAPR-15-0316","article-title":"Whole-genome sequencing of salivary gland adenoid cystic carcinoma","volume":"9","author":"Rettig","year":"2016","journal-title":"Cancer Prev Res"},{"issue":"4","key":"10.1016\/j.eclinm.2024.102991_bib11","doi-asserted-by":"crossref","first-page":"429","DOI":"10.2217\/fon.15.329","article-title":"Unknown primary tumors: is there a future therapeutic role for immune checkpoint inhibitors?","volume":"12","author":"Kourie","year":"2016","journal-title":"Future Oncol"},{"issue":"1","key":"10.1016\/j.eclinm.2024.102991_bib12","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.eclinm.2024.102991_bib13","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1634\/theoncologist.2014-0468","article-title":"Clinical activity of ipilimumab in acral melanoma: a retrospective review","volume":"20","author":"Johnson","year":"2015","journal-title":"Oncol"},{"issue":"11","key":"10.1016\/j.eclinm.2024.102991_bib14","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/nrc3838","article-title":"Translational biology of osteosarcoma","volume":"14","author":"Kansara","year":"2014","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.eclinm.2024.102991_bib15","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/391967","article-title":"Sarcoma immunotherapy: past approaches and future directions","volume":"2014","author":"D'Angelo","year":"2014","journal-title":"Sarcoma"},{"issue":"21","key":"10.1016\/j.eclinm.2024.102991_bib16","doi-asserted-by":"crossref","first-page":"4753","DOI":"10.1158\/1078-0432.CCR-15-0831","article-title":"New strategies in sarcoma: linking genomic and immunotherapy approaches to molecular subtype","volume":"21","author":"Lim","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.eclinm.2024.102991_bib17","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.3802\/jgo.2017.28.e20","article-title":"Update on immune checkpoint inhibitors in gynecological cancers","volume":"28","author":"Heong","year":"2017","journal-title":"J\u00a0Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.eclinm.2024.102991_bib18","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.ygyno.2018.09.001","article-title":"Genomics to immunotherapy of ovarian clear cell carcinoma: unique opportunities for management","volume":"151","author":"Oda","year":"2018","journal-title":"Gynecol Oncol"},{"issue":"4","key":"10.1016\/j.eclinm.2024.102991_bib19","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/S1470-2045(17)30104-3","article-title":"Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study","volume":"18","author":"Morris","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eclinm.2024.102991_bib21","first-page":"48","article-title":"[Therapia antiqua]","volume":"3","author":"Marvitz","year":"1983","journal-title":"Tidsskr Tandlaeger"},{"issue":"34","key":"10.1016\/j.eclinm.2024.102991_bib22","doi-asserted-by":"crossref","first-page":"4015","DOI":"10.1200\/JCO.2015.62.3397","article-title":"Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer","volume":"33","author":"Hamanishi","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.eclinm.2024.102991_bib23","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1277308","article-title":"Clear cell ovarian cancers with microsatellite instability: a unique subset of ovarian cancers with increased tumor-infiltrating lymphocytes and PD-1\/PD-L1 expression","volume":"6","author":"Howitt","year":"2017","journal-title":"OncoImmunology"},{"issue":"16_suppl","key":"10.1016\/j.eclinm.2024.102991_bib24","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.5565","article-title":"A multicenter phase II randomized trial of durvalumab (D) versus physician\u2019s choice chemotherapy (PCC) in patients (pts) with recurrent ovarian clear cell adenocarcinoma (MOCCA\/APGOT-OV2\/GCGS-OV3). ASCO","volume":"40","author":"Tan","year":"2022","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"10.1016\/j.eclinm.2024.102991_bib25","article-title":"Stage 1 results of BrUOG 354: a randomized phase II trial of nivolumab alone or in combination with ipilimumab for people with ovarian and other extra-renal clear cell carcinomas (NCT03355976). ASCO","volume":"40","author":"Don","year":"2022","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.eclinm.2024.102991_bib26","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/jso.24266","article-title":"Programmed death ligand-1 expression is associated with poor disease free survival in salivary gland carcinomas","volume":"114","author":"Mukaigawa","year":"2016","journal-title":"J\u00a0Surg Oncol"},{"issue":"8","key":"10.1016\/j.eclinm.2024.102991_bib27","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/S1470-2045(10)70245-X","article-title":"Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands: a systematic review","volume":"12","author":"Laurie","year":"2011","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.eclinm.2024.102991_bib28","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-49215-9","article-title":"The expression of PD-L1 in salivary gland carcinomas","volume":"9","author":"Vital","year":"2019","journal-title":"Sci Rep"},{"issue":"11","key":"10.1016\/j.eclinm.2024.102991_bib29","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1097\/COC.0000000000000429","article-title":"Pembrolizumab for the treatment of advanced salivary gland carcinoma: findings of the phase 1b KEYNOTE-028 study","volume":"41","author":"Cohen","year":"2018","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.eclinm.2024.102991_bib30","series-title":"A\u00a0phase II trial of nivolumab for patients with platinum-refractory recurrent or metastatic salivary gland cancer","year":"2022"},{"issue":"12","key":"10.1016\/j.eclinm.2024.102991_bib31","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1038\/s41591-023-02518-x","article-title":"Nivolumab plus ipilimumab in advanced salivary gland cancer: a phase 2 trial","volume":"29","author":"Vos","year":"2023","journal-title":"Nat Med"},{"issue":"9","key":"10.1016\/j.eclinm.2024.102991_bib32","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12092516","article-title":"Evaluation of PD-L1 expression and HPV genotyping in anal squamous cell carcinoma","volume":"12","author":"Wessely","year":"2020","journal-title":"Cancers"},{"issue":"5","key":"10.1016\/j.eclinm.2024.102991_bib33","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/S2468-1253(21)00382-4","article-title":"Pembrolizumab for previously treated advanced anal squamous cell carcinoma: results from the non-randomised, multicohort, multicentre, phase 2 KEYNOTE-158 study","volume":"7","author":"Marabelle","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.eclinm.2024.102991_bib34","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1200\/JCO.2002.20.6.1651","article-title":"Gemcitabine, carboplatin, and paclitaxel for patients with carcinoma of unknown primary site: a Minnie Pearl Cancer Research Network study","volume":"20","author":"Greco","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.eclinm.2024.102991_bib35","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ejca.2018.02.021","article-title":"Comprehensive analysis of cancers of unknown primary for the biomarkers of response to immune checkpoint blockade therapy","volume":"94","author":"Gatalica","year":"2018","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.eclinm.2024.102991_bib36","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.annonc.2021.11.009","article-title":"Open-label phase II study of the efficacy of nivolumab for cancer of unknown primary","volume":"33","author":"Tanizaki","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eclinm.2024.102991_bib37","article-title":"Efficacy of pembrolizumab in patients with advanced cancer of unknown primary (CUP): a phase 2 non-randomized clinical trial","volume":"10","author":"Raghav","year":"2022","journal-title":"J\u00a0Immunother Cancer"},{"issue":"11","key":"10.1016\/j.eclinm.2024.102991_bib38","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/S1470-2045(17)30624-1","article-title":"Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial","volume":"18","author":"Tawbi","year":"2017","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.eclinm.2024.102991_bib39","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/S1470-2045(18)30006-8","article-title":"Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials","volume":"19","author":"D'Angelo","year":"2018","journal-title":"Lancet Oncol"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537024005704?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537024005704?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T20:10:30Z","timestamp":1750450230000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537024005704"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":38,"alternative-id":["S2589537024005704"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2024.102991","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Durvalumab and tremelimumab in patients with advanced rare cancer: a multi-centre, non-blinded, open-label phase II basket trial","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2024.102991","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102991"}}